The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
Vaccine
; 38(49): 7708-7715, 2020 11 17.
Article
em En
| MEDLINE
| ID: mdl-32907759
ABSTRACT
Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe the key considerations for the benefit-risk assessment of viral vector vaccines. This will facilitate key stakeholders to anticipate potential safety issues and interpret or assess safety data. This would also help improve communication and public acceptance of licensed viral vector vaccines.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vacinas Atenuadas
/
Vacinas Virais
/
Avaliação Pré-Clínica de Medicamentos
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article